Govt needs to protect vaccine manufacturers against all lawsuits, says SII CEO Adar Poonawalla

Last month, SII had rejected allegations of serious side-effects made by a participant in the Covishield vaccine trial in Chennai. The man had also sought Rs 5 crore compensation

Press Trust of India December 20, 2020 16:34:39 IST
Govt needs to protect vaccine manufacturers against all lawsuits, says SII CEO Adar Poonawalla

Adar Poonawalla. Twitter@adarpoonawalla

New Delhi: Vaccine manufacturers need to have protection against all lawsuits for their vaccines especially during a pandemic, Serum Institute of India (SII) chief executive officer Adar Poonawalla has said.

He also said that the vaccine makers are going to propose this to the government while speaking at a virtual panel on the challenges of developing a COVID-19 vaccine at Carnegie India's Global Technology Summit on Friday.

"We need to have the government indemnify manufacturers, especially vaccine manufacturers, against all lawsuits. In fact, COVAX and other countries have already started talking about that," Poonawalla said.

It is because when frivolous claims come up, and something is blown out of proportion in the media, skepticism sets in that definitely something can happen due to the vaccine, and to dispel that, the government needs to step in to spread the right information, he added.

"..the government can act, the US, for example, has in fact invoked a law, to say that during a pandemic, and this is especially important only during a pandemic, to indemnify vaccine manufacturers against lawsuits for severe adverse effects or any other frivolous claims which may come about, because that adds to the fear and also will bankrupt vaccine manufacturers or distract them if they have to just all-day fight lawsuits and explain to the media what is happening," Poonawalla said.

These are a few things that the government can do and that is what the vaccine manufacturers are going to propose, he added.

Last month, Serum had rejected the charges that a 40-year-old man who took part in the 'Covishield' vaccine trial in Chennai had levelled against the company. The man had alleged serious side effects, including a virtual neurological breakdown and impairment of cognitive functions.

He had also sought Rs 5 crore compensation in a legal notice to Serum and others, besides seeking a halt on the trial.

Refuting the charges, Serum had said, "It is evident that the intention behind spreading such malicious information is an oblique pecuniary motive. The Serum Institute of India will seek damages in excess of Rs 100 crore for the same and will defend such malicious claims".

Updated Date:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Centre orders 11 mn doses of Oxford-AstraZeneca vaccine from SII at Rs 210 each
India

Centre orders 11 mn doses of Oxford-AstraZeneca vaccine from SII at Rs 210 each

Doses of the vaccine, Covishield, will initially be shipped to 60 consignee points and will then be distributed to various vaccination centres across India

India sends over 20 lakh free doses of COVID-19 vaccine to Bangladesh; Dhaka praises 'gift of goodwill'
India

India sends over 20 lakh free doses of COVID-19 vaccine to Bangladesh; Dhaka praises 'gift of goodwill'

Apart from the current delivery of vaccines, Bangladesh is also set to purchase 3 crore doses of India-made vaccine under a tripartite memorandum of understanding (MoU) signed with SII

COVID-19 vaccination: First Covishield consignment leaves Serum Institute, to be sent to 13 locations
India

COVID-19 vaccination: First Covishield consignment leaves Serum Institute, to be sent to 13 locations

The vaccines will be flown from Pune in eight commercial flights, including two cargo flights, a source told PTI